CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.

The ability of a motif of the CYP17 5' untranslated region, created by a polymorphic T to C substitution, to bind to the human transcription factor Sp-1 was investigated. No binding of any of the polymorphic alleles was observed in electromobility shift assay. No other sequence within +1 to +100 of each of the CYP17 alleles formed complex with the Sp-1 or enhanced binding to the polymorphic CACC box. Genotyping of 510 breast cancer patients and 201 controls revealed no difference in genotype frequencies. Age at onset, tumor grade, lymph node status and distant metastases, stage, and estrogen and progesterone receptor status were not associated with the CYP17 genotype.

[1]  R. Voutilainen,et al.  Developmental expression of genes for the stereoidogenic enzymes P450scc (20,22-desmolase), P450c17 (17 alpha-hydroxylase/17,20-lyase), and P450c21 (21-hydroxylase) in the human fetus. , 1986, The Journal of clinical endocrinology and metabolism.

[2]  R. Tjian,et al.  Multiple specific contacts between a mammalian transcription factor and its cognate promoters , 1984, Nature.

[3]  R. Santen,et al.  Resistance of the ovary to blockade of aromatization with aminoglutethimide. , 1980, The Journal of clinical endocrinology and metabolism.

[4]  S. Franks,et al.  Evidence for a single gene effect causing polycystic ovaries and male pattern baldness , 1993 .

[5]  Robert Tjian,et al.  Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain , 1987, Cell.

[6]  I. Bleiweiss,et al.  CYP17 genotype and breast cancer risk. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  G. Coetzee,et al.  A polymorphism in the CYP17 gene increases the risk of breast cancer. , 1997, Cancer research.

[8]  R. Kåresen,et al.  Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas , 1997, The Journal of pathology.

[9]  M. Pike,et al.  Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. , 1998, Cancer research.

[10]  W. Miller,et al.  Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. , 1987, DNA.

[11]  C. Martucci,et al.  P450 enzymes of estrogen metabolism. , 1993, Pharmacology & therapeutics.

[12]  P. Hall,et al.  C21 steroid side chain cleavage enzyme from porcine adrenal microsomes. Purification and characterization of the 17 alpha-hydroxylase/C17,20-lyase cytochrome P-450. , 1984, The Journal of biological chemistry.

[13]  J. Manson,et al.  Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.

[14]  A. Friedman,et al.  C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter , 1996, Molecular and cellular biology.

[15]  B. Ponder,et al.  No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. , 1998, British Journal of Cancer.

[16]  M. Dowsett,et al.  A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. , 1997, British Journal of Cancer.

[17]  D. Bell,et al.  Association between CYP17 polymorphisms and the development of breast cancer. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[18]  C. Y. Yu,et al.  The CACC box upstream of human embryonic epsilon globin gene binds Sp1 and is a functional promoter element in vitro and in vivo. , 1991, The Journal of biological chemistry.

[19]  B. Henderson,et al.  Estrogens and breast cancer. , 1996, Carcinogenesis.